OXFORD, Engeland & WENEN, Oostenrijk–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI) heeft vandaag details gedeeld over haar deelname aan de komende jaarlijkse bijeenkomst van de American Association voor Cancer Research (AACR), die plaatsvindt van 8-13 april 2022 in de Ernest N. Morial Convention Center in New Orleans, La. Wetenschappers van Exscientia zullen nieuw onderzoek presenteren in drie posterpresentaties.

“We kijken ernaar uit om een ​​aantal van ‘s werelds toonaangevende kankermedici en onderzoekers te ontmoeten tijdens de AACR-bijeenkomst van dit jaar, terwijl we doorgaan met het bouwen van ons platform voor precisiegeneeskunde op het gebied van menselijk weefsel en de gebieden die we onderzoeken uitbreiden met aanvullende indicaties zoals borst- en eierstokkanker”, zegt Nikolaus Krall, Exscientia’s VP Precision Medicine. “Bovendien zullen we gegevens delen die onze translationele onderzoekscapaciteiten en AI-gedreven platform voor het ontdekken van geneesmiddelen en het potentieel om de ontdekking van kankermedicijnen te herdefiniëren, benadrukken. We zijn van mening dat deze onderzoeken onze nieuwe benaderingen blijven valideren terwijl we proberen de klinische en patiëntresultaten te verbeteren door efficiënt de meest veelbelovende therapeutische activa te identificeren.”

Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022

OXFORD, England & VIENNA, Austria–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI) today shared details of its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13 2022 at the Ernest N. Morial Convention Center in New Orleans, La. Exscientia scientists will present new research in three poster presentations.

“We are looking forward to meeting with some of the world’s leading cancer clinicians and researchers at this year’s AACR meeting, as we continue to build our human tissue precision medicine platform and expand the areas we are exploring to include additional indications such as breast and ovarian cancers,” said Nikolaus Krall, Exscientia’s VP of Precision Medicine. “In addition, we will share data highlighting our translational research capabilities and AI-driven drug discovery platform and the potential to redefine cancer drug discovery. We believe these studies continue to validate our novel approaches as we seek to improve clinical and patient outcomes by efficiently identifying the most promising therapeutic assets.”

Exscientia will have a booth (#2016) where attendees can meet the team and learn more about the company’s AI-driven precision oncology platform, broad pipeline, and newly launched collaboration with the University of Oxford, Xcellomics™, to help accelerate early-stage drug discovery.

Poster presentations:

Poster Title: Enriching for adenosine antagonist patient responses through deep learning
Session Title: Immunomodulatory Agents and Interventions

Abstract Number: #4150

Date/Time: Wednesday, April 13 / 9:00 AM – 12:30 PM CT

Poster Title: AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7
Session Title: Emerging New Anticancer Agents

Abstract Number: #3930

Date/Time: Wednesday, April 13 / 9:00 AM – 12:30 PM CT

Poster Title: Deep Learning Supported Analysis of Primary Samples Identifies ALK Pathway as a Novel Sensitivity in Ovarian Cancer
Session Title: New Technologies for Drug Discovery

Abstract Number: #1893

Date/Time: Monday, April 11 / 1:30 PM – 5:00 PM CT

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 30 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations with respect to the progress of development of candidate molecules, timing and progress of, and data reported from, preclinical studies and clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding its precision medicine platform and AI-driven drug discovery platform. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions, including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005536/en/

Contacts

Investors:
Sara Sherman

investors@exscientia.ai

Media:
Amanda Galgay

media@exscientia.ai